Media Tips

Beaumont’s Radiation Oncology research receives national attention

Two lung cancer studies published by researchers from Beaumont Health System’s department of Radiation Oncology were recognized this past fall at the annual meeting of the American Society for Radiation Oncology. In fact, one of the studies was named “Best of ASTRO.”

ASTRO's annual meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees. 

Researcher and radiation oncologist, Inga Grills, M.D., an author on each of the two highlighted studies, says, “Both are important works.”

One study focused on clinical outcomes and the other patient safety.

“A Matched Pair Analysis of Stage 1 Non-Small Cell Lung Cancer Treated with Lobectomy, Stereotactic Radiation Therapy or Wedge Resection,” compared the outcomes of early-stage lung cancer treated with CT image-guided radiation with surgery. They found that five days of noninvasive stereotactic radiation works as well traditional wedge resection surgery.

“Toxicity After Central Versus Peripheral Stereotactic Lung Radiation Therapy: A Propensity Score Matched-Pair Analysis,” compared the safety of radiation used to treat tumors in the center and periphery of the lung with focused stereotactic radiation in only four or five treatments. While this radiation has been very effective in treating central tumors, severe toxicities have been reported using higher doses than in the Beaumont study. When patients are not good candidates for surgery, stereotactic radiation is the therapy of choice. This study named “Best of ASTRO” found that moderate doses of stereotactic radiation appeared safe for tumors in both the center and outer boundaries of the lung.

FDA approved once-a-day pill for Hepatitis C

The Food and Drug Administration has approved a high-potency, once-a-day pill to cure Hepatitis C, a viral infection affecting the liver. According to the CDC, an estimated 3.2 million people in the U.S. have chronic Hepatitis C. Beaumont hepatologist, Mohammed Al Sibae, M.D. is available to discuss the new treatment.